Curated News
By: NewsRamp Editorial Staff
August 24, 2026
VERAXA and Secarna Report Positive Early Data for AOCs in Autoimmune Diseases
TLDR
- VERAXA's AOC collaboration with Secarna shows superior potency, potentially expanding beyond tumors to autoimmune diseases, offering a competitive edge.
- In vitro studies combined VERAXA's click chemistry conjugation with Secarna's oligonucleotides, demonstrating enhanced potency compared to unconjugated versions, validating the approach.
- This collaboration aims to develop targeted therapies for autoimmune and chronic immune diseases, potentially improving patient outcomes and quality of life.
- AOC candidates using click chemistry could deliver therapeutic oligonucleotides precisely to disease-specific cells, a novel approach beyond solid tumors.
Impact - Why it Matters
This news matters because it suggests that antibody oligonucleotide conjugates (AOCs) could become a new class of therapeutics for autoimmune and chronic immune diseases, offering targeted delivery that may enhance efficacy and reduce side effects compared to unconjugated oligonucleotides. For patients, this could mean more effective treatments with fewer adverse effects. For the biotech industry, it validates the potential of combining different technologies to create novel therapies, potentially opening new avenues for drug development beyond oncology.
Summary
VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration aimed at developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate combining the companies' technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of the approach to selectively deliver therapeutic oligonucleotides to disease-specific cells. The companies said they are discussing next steps in the collaboration, which VERAXA noted demonstrates the potential application of its proprietary click chemistry-powered conjugation technology beyond its primary focus on solid tumors.
VERAXA Biotech AG is a biopharmaceutical company focused on developing next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company leverages transformative technologies and rigorous quality-by-design principles to advance its pipeline of ADCs and proprietary BiTAC formats into clinical development. Founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), VERAXA is committed to pioneering life science research. The collaboration with Secarna, a leader in antisense oligonucleotide therapeutics, combines VERAXA's conjugation expertise with Secarna's Locked Nucleic Acid (LNA) platform to create AOCs that can precisely target disease-related cells.
This news is part of a broader effort to expand the application of AOCs beyond oncology into chronic immune conditions, potentially offering new treatment options for patients with autoimmune diseases. The initial positive results are a promising step, but further studies are needed to confirm the efficacy and safety of these conjugates. The companies' ongoing discussions indicate a continued commitment to advancing this innovative therapeutic approach.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA and Secarna Report Positive Early Data for AOCs in Autoimmune Diseases
